To clarify the distinction between tracheobronchial drug exposure and parenchymal target achievement in the context of nebulized amikacin therapy.
Key Findings:
Tracheobronchial drug exposure is relevant for airway decontamination but less so for treating established pneumonia.
The AMIKINHAL trial supports inhaled amikacin for preventing ventilator-associated pneumonia, while the INHALE trial does not support its use for established pneumonia.
Experimental data show that while inhaled amikacin can reduce bacterial burden in proximal airways, it does not improve pulmonary tissue colonization.
Interpretation:
The study by Gregoire et al. demonstrates effective tracheobronchial delivery of amikacin with minimal systemic exposure, but this does not guarantee effective treatment of pneumonia.
Limitations:
The study's focus on tracheal aspirate may not reflect the drug's effectiveness in infected pulmonary parenchyma.
Current pharmacokinetic endpoints may not adequately capture relevant therapeutic outcomes for pneumonia treatment.
Conclusion:
Future trials should differentiate between prophylactic and treatment strategies for inhaled antibiotics and focus on relevant pharmacokinetic measures for effective clinical outcomes.
Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.
